X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
index medicus (11) 11
oncology (10) 10
male (9) 9
adult (8) 8
female (8) 8
chemotherapy (7) 7
middle aged (7) 7
cancer (6) 6
temozolomide (6) 6
aged (5) 5
care and treatment (5) 5
clinical trials (5) 5
hematology, oncology and palliative medicine (5) 5
radiation therapy (5) 5
radiotherapy (5) 5
brain neoplasms - drug therapy (4) 4
brain neoplasms - mortality (4) 4
gliomas (4) 4
lymphomas (4) 4
medical prognosis (4) 4
procarbazine (4) 4
tumors (4) 4
young adult (4) 4
adolescent (3) 3
bevacizumab (3) 3
biopsy (3) 3
brain cancer (3) 3
brain neoplasms - therapy (3) 3
brain tumors (3) 3
cancer therapies (3) 3
clinical neurology (3) 3
dacarbazine - analogs & derivatives (3) 3
dacarbazine - therapeutic use (3) 3
disease-free survival (3) 3
elderly-patients (3) 3
glioblastoma (3) 3
glioblastoma multiforme (3) 3
lomustine (3) 3
lomustine - administration & dosage (3) 3
neoplasm recurrence, local - drug therapy (3) 3
neoplasm staging (3) 3
neurology (3) 3
patients (3) 3
quality of life (3) 3
radiation-therapy (3) 3
response assessment (3) 3
studies (3) 3
survival (3) 3
term-follow-up (3) 3
toxicity (3) 3
treatment outcome (3) 3
trial (3) 3
adjuvant temozolomide (2) 2
aged, 80 and over (2) 2
analysis (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents, alkylating - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
brain neoplasms - radiotherapy (2) 2
brain research (2) 2
child (2) 2
clinical-trials (2) 2
cognition (2) 2
diagnosis (2) 2
diseases (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
efficacy (2) 2
flow cytometry (2) 2
follow-up studies (2) 2
glioblastoma - drug therapy (2) 2
glioblastoma - mortality (2) 2
glioma - drug therapy (2) 2
glioma - mortality (2) 2
high-dose methotrexate (2) 2
histology (2) 2
lomustine - adverse effects (2) 2
lymphoma (2) 2
magnetic resonance imaging (2) 2
malignant glioma (2) 2
medical and health sciences (2) 2
medical research (2) 2
medicin och hälsovetenskap (2) 2
medicine & public health (2) 2
methylation (2) 2
neoplasm invasiveness - pathology (2) 2
nervous system (2) 2
nervous-system lymphoma (2) 2
newly-diagnosed glioblastoma (2) 2
non-hodgkins-lymphoma (2) 2
o6-methylguanine-dna methyltransferase (2) 2
plus irinotecan (2) 2
prospective studies (2) 2
relapse (2) 2
retrospective studies (2) 2
rituximab (2) 2
single-agent bevacizumab (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 943 - 953
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1533 - 1542
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1521 - 1532
Journal Article
Haematologica, ISSN 0390-6078, 07/2014, Volume 99, Issue 7, pp. 1228 - 1235
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 10, pp. 1321 - 1330
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Methylation | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2019, Volume 20, Issue 2, pp. 216 - 228
The prognosis for primary CNS lymphoma has improved with the use of high-dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a... 
IMMUNOCHEMOTHERAPY | ONCOLOGY | HIGH-DOSE METHOTREXATE | IMPROVED SURVIVAL | WHOLE-BRAIN RADIOTHERAPY | CYTARABINE | ELDERLY-PATIENTS | PROCARBAZINE | NERVOUS-SYSTEM LYMPHOMA | CHEMOTHERAPY | TEMOZOLOMIDE | Professional hockey | Care and treatment | Lymphomas | Analysis
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 05/2012, Volume 108, Issue 1, pp. 195 - 200
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2015, Volume 51, Issue 10, pp. 1321 - 1330
Background: The BELOB study, a randomised controlled phase 2 trial comparing lomustine, bevacizumab and combined lomustine and bevacizumab in patients with... 
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2015, Volume 51, Issue 10, p. 1321
Background The BELOB study, a randomised controlled phase 2 trial comparing lomustine, bevacizumab and combined lomustine and bevacizumab in patients with... 
Journal Article